Factors interacting with HIF-1α mRNA: Novel therapeutic targets

Current Pharmaceutical Design

Volumn 15, Issue 33, 2009, Pages 3853-3860

  Galbán, Stefanie ^a   Gorospe, Myriam ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antisense RNA; IRES; microRNA; Post transcriptional gene regulation; RNA binding proteins

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; CYCLIC AMP BINDING PROTEIN; CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN; CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN 1; CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN 2; EZN 2968; HUMAN ANTIGEN R; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOSUPPRESSIVE AGENT; IRON REGULATORY FACTOR; LOCKED NUCLEIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; PATEAMINE A; POLYPYRIMIDINE TRACT BINDING PROTEIN; RAPAMYCIN; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSFERRIN; UNCLASSIFIED DRUG; WORTMANNIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; BINDING AFFINITY; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENE SILENCING; HALF LIFE TIME; HUMAN; HYPOXIA; INTERNAL RIBOSOME ENTRY SITE; MELANOMA; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; PROTEIN SYNTHESIS REGULATION; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; RNA STABILITY; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; TRANSLATION REGULATION; UPREGULATION;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HALF-LIFE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER;

EID: 70649108815     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789649376     Document Type: Review

References (77)

1. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-17
2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799 (Pubitemid 39070849)
3. Bracken CP, Whitelaw ML, Peet DJ. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 2003; 60: 1376-1393
4. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008; 60: 591-597
5. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; (306): re12.
6. Minet E, Ernest I, Michel G, Roland I, Remacle J, Raes M, et al. HIF1A gene transcription is dependent on a core promoter sequence encompassing activating and inhibiting sequences located upstream from the transcription initiation site and cis elements located within the 5'UTR. Biochem Biophys Res Commun 1999; 261: 534-540 (Pubitemid 29392511)
7. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005; 37: 535-540 (Pubitemid 40022930)
8. Galbán S, Kuwano Y, Pullmann R Jr, Martindale JL, Kim HH, Lal A, et al. RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2008; 28: 93-107.
9. Belaiba RS, Bonello S, Zähringer C, Schmidt S, Hess J, Kietzmann T, et al. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 2007; 18: 4691-4697 (Pubitemid 350246672)
10. Sperandio S, Fortin J, Sasik R, Robitaille L, Corbeil J, de Belle I. The transcription factor Egr1 regulates the HIF-1alpha gene during hypoxia. Mol Carcinog 2009; 48: 38-44.
11. Moore MJ. From birth to death: the complex lives of eukaryotic mRNAs. Science 2005; 309: 1514-1518
12. Keene JD. RNA regulons: coordination of post-transcriptional events. Nat Rev Genet 2007; 8: 533-543
13. Abdelmohsen K, Kuwano Y, Kim HH, Gorospe M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol Chem 2008; 389: 243-255 (Pubitemid 351329020)
14. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15: R17-29.
15. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E, et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 2004; 279: 14871-14878
16. Sheflin LG, Zou AP, Spaulding SW. Androgens regulate the binding of endogenous HuR to the AU-rich 3′UTRs of HIF-1alpha and EGF mRNA. Biochem Biophys Res Commun 2004; 322: 644-651
17. Chachami G, Simos G, Hatziefthimiou A, Bonanou S, Molyvdas PA, Paraskeva E. Cobalt induces hypoxia-inducible factor-1α expression in airway smooth muscle cells by a reactive oxygen species- and PI3Kdependent mechanism. Am J Respir Cell Mol Biol 2004; 31: 544-551 (Pubitemid 39463403)
18. Hui AS, Bauer AL, Striet JB, Schnell PO, Czyzyk-Krzeska MF. Calcium signaling stimulates translation of HIF-alpha during hypoxia. FASEB J 2006; 20: 466-475
19. Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H, et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res 2008; 68: 5540-5545
20. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, et al. Downregulation of MiR-199a derepresses hypoxia-inducible factor-1α and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009; 104(7): 879-886
21. Hägele S, Kühn U, Böning M, Katschinski DM. Cytoplasmic polyadenylation-element-binding protein (CPEB)1 and 2 bind to the HIF-1alpha mRNA 3′-UTR and modulate HIF-1alpha protein expression. Biochem J 2009; 417: 235-246
22. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004. (Pubitemid 46646218)
23. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343-354
24. Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 2005; 338: 617-626
25. Goldberg MA, Gaut CC, Bunn HF. Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood 1991; 77: 271-277
26. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333-13340
27. Bruckner BA, Ammini CV, Otal MP, Raizada MK, Stacpoole PW. Regulation of brain glucose transporters by glucose and oxygen deprivation. Metabolism 1999; 48: 422-431 (Pubitemid 29174218)
28. Shaw G, Kamen RA. Conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 659-667
29. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995; 20: 465-470
30. Schepens B, Tinton SA, Bruynooghe Y, Beyaert R, Cornelis S. The polypyrimidine tract-binding protein stimulates HIF-1alpha IRES-mediated translation during hypoxia. Nucleic Acids Res 2005; 33: 6884-6894 (Pubitemid 41830492)
31. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65:3168-3181
32. Sawicka K, Bushell M, Spriggs KA, Willis AE. Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans 2008; 36: 641-647
33. He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW. The antisense transcriptomes of human cells. Science 2008; 322: 1855-1857
34. Rossignol F, de Laplanche E, Mounier R, Bonnefont J, Cayre A, Godinot C, et al. Natural antisense transcripts of HIF-1alpha are conserved in rodents. Gene 2004; 339: 121-130 (Pubitemid 39201134)
35. Kraggerud SM, Sandvik JA, Pettersen EO. Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res 1995; 15: 683-686
36. Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 2008; 33: 526-534
37. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68: 913-963 (Pubitemid 29449212)
38. Zhou J, Brune B. Cytokines and hormones in the regulation hypoxia inducible factor-1 (HIF-1). Cardiovasc Hematol Agents Med Chem 2006; 4: 189-197 (Pubitemid 44027709)
39. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122-127 (Pubitemid 43050086)
40. Knaup KX, Jozefowski K, Schmidt R, Bernhardt WM, Weidemann A, Juergensen JS, et al. Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability. Mol Cancer Res 2009; 7: 88-98.
41. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular growth factor. Nat Med 2002; 8: 128-135 (Pubitemid 34155123)
42. Lang KJ, Kappel A, Goodall GJ. Hypoxia-inducible factor-1 contains an interna ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 2002; 13, 1792-1801. (Pubitemid 34522656)
43. Zhou J, Callapina M, Goodall GJ, Brüne B. Functional integrity of nuclear factor kB, phosphatidylinositol 30-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor aevoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxiainducible factor 1a. Cancer Res 2004; 64: 9041-9048
44. Merrick WC. Cap-dependent and cap-independent translation in eukaryotic systems. Gene 2004; 332: 1-11.
45. Bert AG, Grépin R, Vadas MA, Goodall GJ. Assessing IRES activity in the HIF-1alpha and other cellular 5′ UTRs. RNA 2006; 12: 1074-1083 (Pubitemid 43788125)
46. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 2008; 283: 16309-16319
47. Mazan-Mamczarz K, Galbán S, López de Silanes I, Martindale JL, Atasoy U, Keene JD, et al. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci USA 2003; 100:8354-8359 (Pubitemid 36842549)
48. Lal A, Kawai T, Yang X, Mazan-Mamczarz K, Gorospe M. Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha. EMBO J 2005; 24: 1852-1862 (Pubitemid 40769504)
49. Kawai T, Lal A, Yang X, Galban S, Mazan-Mamczarz K, Gorospe M. Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR. Mol Cell Biol 2006; 26: 3295-3307
50. Kuwano Y, Kim HH, Abdelmohsen K, Pullmann R Jr, Martindale JL, Yang X, et al. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol 2008; 28: 4562-4575 (Pubitemid 351977754)
51. Kullmann M, Göpfert U, Siewe B, Hengst L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′UTR. Genes Dev 2002; 16: 3087-3099
52. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006; 125:1111-1124 (Pubitemid 43866197)
53. Meng Z, Jackson NL, Choi H, King PH, Emanuel PD, Blume SW. Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells. J Cell Physiol 2008; 217: 172-183
54. Grover R, Ray PS, Das S. Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. Cell Cycle 2008; 7: 2189-2198 (Pubitemid 352031521)
55. Leipuviene R, Theil EC. The family of iron responsive RNA structures regulated by changes in cellular iron and oxygen. Cell Mol Life Sci 2007; 64: 2945-2955 (Pubitemid 351152243)
56. Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, et al. Small-molecule inhibitors of HIF-2a translation link its 5′UTR iron-responsive element to oxygen sensing. Mol Cell 2008; 32: 838-848
57. Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M. miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci USA 2008; 105: 20297-20302
58. Meisner NC, Hintersteiner M, Mueller K, Bauer R, Seifert JM, Naegeli HU, et al. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat Chem Biol 2007; 3: 508-515 (Pubitemid 47080371)
59. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273: 6417-6423 (Pubitemid 28144735)
60. Gantt KR, Cherry J, Richardson M, Karschner V, Atasoy U, Pekala PH. The regulation of glucose transporter (GLUT1) expression by the RNA binding protein HuR. J Cell Biochem 2006; 99: 565-574 (Pubitemid 44435573)
61. López de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2: 11-13
62. Hood KA, West LM, Northcote PT, Berridge MV, Miller JH. Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine. Apoptosis 2001; 6: 207-219
63. Low WK, Dang Y, Schneider-Poetsch T, Shi Z, Choi NS, Merrick WC, et al. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell 2005; 20: 709-722 (Pubitemid 41740693)
64. Bordeleau ME, Matthews J, Wojnar JM, Lindqvist L, Novac O, Jankowsky E, et al. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci USA 2005; 102: 10460-10465 (Pubitemid 41061576)
65. Romo D, Choi NS, Li S, Buchler I, Shi Z, Liu JO. Evidence for separate binding and scaffolding domains in the immunosuppressive and antitumor marine natural product, pateamine a: design, synthesis, and activity studies leading to a potent simplified derivative. J Am Chem Soc 2004; 126: 10582-10588 (Pubitemid 39129157)
66. Korneeva NL. Translational dysregulation by Pateamine A. Chem Biol 2007; 14: 5-7.
67. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004; 3: 647-654 (Pubitemid 39193744)
68. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008; 7: 90-100.
69. Tafech A, Bassett T, Sparanese D, Lee CH. Destroying RNA as a therapeutic approach. Curr Med Chem 2006; 13: 863-881
70. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005; 5: 468-479
71. Wang JH, Hendry BM, Sharpe CC. Silencing genes in the kidney: antisense or RNA interference? Nephrol Dial Transplant 2008; 23: 2115-2118
72. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258 (Pubitemid 41161256)
73. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006; 126: 231-235
74. Koch T, OrumH. Locked nucleic acid. In: Crooke ST, Ed. Antisense drug technology: principles, strategies, and applications. Florida: CRC Press 2008; p. 519-565
75. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004; 43: 13233-13241 (Pubitemid 39391124)
76. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008; 7: 3598-3608
77. Liu Y, Tao J, Li Y, Yang J, Yu Y, Wang M, et al. Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther 2009; 17: 269-277